King of Prussia, Pennsylvania-based Trice Medical, a private diagnostics company focused on micro invasive technologies, has appointed Craig Carra as its chief financial officer. Previously, Carra worked at Ella Health where he served as the financial and business development leader. Trice Medical is backed by HealthQuest Capital, Safeguard Scientifics and BioStar Ventures.
King of Prussia, PA (PRWEB) February 11, 2015
Trice Medical™, a private diagnostics company focused on micro invasive technologies, today announced the appointment of Craig Carra to the newly created position of Chief Financial Officer. Mr. Carra has spent the majority of his 20-year career holding various executive level positions with emerging growth, medical device and service companies.
“It’s an exciting time for Trice Medical as we build out our team and infrastructure in preparation for commercializing our initial diagnostic arthroscopy product, mi-eye™,” stated Jeffrey F. O’Donnell Sr., Chairman and CEO of Trice Medical. “We are thrilled to have Craig join our executive team. His strong background in medical devices, operations, finance, sales and business development are invaluable components to the future success of Trice Medical. On the heels of closing an $18.1 million Series B financing, we continue to execute against our goal to commercialize mi-eye in the summer of 2015.”
“I am excited to join Jeff and the rest of the management team at Trice Medical as we look to commercialize mi-eye and execute our business plan,” said Mr. Carra. “The Trice Medical team has built a revolutionary orthopedic product that is changing the way physicians view diagnostic procedures and I look forward to using my diverse background and industry experience to add value for Trice Medical and our investors.”
Mr. Carra’s career started as an auditor with Coopers & Lybrand (PricewaterhouseCoopers). From 1996-2002, he served as Corporate Controller and Treasurer for Surgical Laser Technologies, a medical device company where he lead operational efficiencies with strict cash flow management to restore this turn-around Company and enabled it to grow through acquisition. From 2002-2012, Mr. Carra served as VP Sales and Business Development for PhotoMedex. Combining his financial and operational background with his strategic thinking and leadership ability, Mr. Carra built a strong U.S. sales team and developed new business models to significantly increase both annual recurring revenue and capital equipment sales. Prior to Trice Medical, Mr. Carra served as the financial and business development leader for Ella Health, a venture backed, healthcare services company. At Ella Health, Mr. Carra was responsible for securing new equity and debt financing to support the growth of the business and was successful in establishing strategic partnerships with physicians to open several new health centers.
Mr. Carra holds a B.S. in Accounting (Magna Cum Laude) from Saint Joseph’s University and an Executive M.B.A. from Villanova University. Mr. Carra is a Certified Public Accountant.
Trice Medical’s mi-eye device is designed to provide a more immediate, definitive and less expensive diagnosis, eliminating the false reads of indirect modalities, such as MRIs. mi-eye is a fully disposable, single-use, streamlined visualization device that uses a standard 14-gauge needle with an integrated camera and light source to perform a diagnostic arthroscopy—all while in the physician’s office during the initial consultation. A separate LCD tablet, running on Android OS, is attached via a data cable from the mi-eye needle. mi-eye is delivered to customers in sterile packaging and ready for immediate use.
About Trice Medical™
Trice was founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payer by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled needle technologies that provide a clinical solution that is optimized for the physician’s office. Trice’s mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. For more information, please visit http://www.TriceMedical.com.